---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-175433"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:35:54.034294+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atea Q2 net loss $37.2M ($0.44/shr); cash $379.7M; repurchases shares; strategic review ongoing

## Summary
- Net loss of $37.2M ($0.44 diluted EPS) vs $40.5M loss in Q2 2024; R&D expense $32.3M, down $2.4M YoY.
- Cash, equivalents and marketable securities $379.7M at June 30, 2025, down from $454.7M at Dec 31, 2024.
- Board authorized up to $25M share repurchase; 4.6M shares bought at avg $3.01 through June 30.
- Engaged Evercore to evaluate strategic alternatives including partnerships, M&A, or sale of assets.
- Global Phase 3 HCV program (C-BEYOND, C-FORWARD) enrolling on track; 98% SVR12 in Phase 2 per-protocol population.

## SEC filing metadata
- accession: 0001193125-25-175433
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525175433/0001193125-25-175433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525175433/d921944d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-175433
- JSON: https://secwatch.observer/filing/0001193125-25-175433.json
- Plain text: https://secwatch.observer/filing/0001193125-25-175433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.